Skip to main content
Erschienen in: Clinical and Experimental Nephrology 5/2010

01.10.2010 | Case Report

Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone

verfasst von: Daisuke Katagiri, Maki Shibata, Takashi Katsuki, Shoichi Masumoto, Ai Katsuma, Eri Minami, Taro Hoshino, Tsuyoshi Inoue, Manami Tada, Fumihiko Hinoshita

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

An elderly patient with pure red cell aplasia (PRCA) with antierythropoietin (anti-EPO) antibodies is described. PRCA due to alloimmunization is a rare and severe complication of recombinant human erythropoietin (rHu-EPO) therapy. Most reported patients with PRCA were cured primarily by immunosuppressive drug therapy. The patient in this case, however, did not want to receive any immunosuppressive drugs. Therefore, rHu-EPO injection was simply discontinued, the severe anemia gradually improved, and the hemoglobin approached normal range. This case is very rare and significant in that there have been few such elderly patients with rHu-EPO-induced PRCA in whom PRCA remission was achieved, with decreasing antibody titers, after cessation of rHu-EPO alone. Further cases are needed to assess how PRCA should be treated in patients with anti-EPO antibodies.
Literatur
1.
Zurück zum Zitat Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–75.CrossRefPubMed Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–75.CrossRefPubMed
2.
Zurück zum Zitat Shinohara K, Mitani N, Miyazaki M, Sakuragi S, Matsuda K, Ogawara S, et al. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure. Am J Hematol. 2005;78:15–20.CrossRefPubMed Shinohara K, Mitani N, Miyazaki M, Sakuragi S, Matsuda K, Ogawara S, et al. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure. Am J Hematol. 2005;78:15–20.CrossRefPubMed
3.
Zurück zum Zitat Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002;13:2381–3.CrossRefPubMed Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002;13:2381–3.CrossRefPubMed
4.
Zurück zum Zitat Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract. 2004;96:c88–95.CrossRefPubMed Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract. 2004;96:c88–95.CrossRefPubMed
5.
Zurück zum Zitat Rossert J. Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur J Clin Invest. 2005;35(Suppl 3):95–9.PubMed Rossert J. Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur J Clin Invest. 2005;35(Suppl 3):95–9.PubMed
6.
Zurück zum Zitat Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004;363:1768–71.CrossRefPubMed Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004;363:1768–71.CrossRefPubMed
7.
Zurück zum Zitat Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005;106:3343–7.CrossRefPubMed Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005;106:3343–7.CrossRefPubMed
8.
Zurück zum Zitat Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol. 2000;111:1010–22.CrossRefPubMed Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol. 2000;111:1010–22.CrossRefPubMed
9.
Zurück zum Zitat Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–7.CrossRefPubMed Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–7.CrossRefPubMed
10.
Zurück zum Zitat Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891–8.CrossRefPubMed Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891–8.CrossRefPubMed
11.
Zurück zum Zitat Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol. 1997;47:331–5.PubMed Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol. 1997;47:331–5.PubMed
12.
Zurück zum Zitat Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. 1996;334:630–3.CrossRefPubMed Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. 1996;334:630–3.CrossRefPubMed
13.
Zurück zum Zitat Viron B, Dupuy CA, Kolta A, Casadevall N. Successful re-challenge with darbepoetin in a patient with rHu-EPO-induced pure red cell aplasia refractory to immunosuppressive drugs. Nephrol Dial Transpl. 2008;23:2416–8.CrossRef Viron B, Dupuy CA, Kolta A, Casadevall N. Successful re-challenge with darbepoetin in a patient with rHu-EPO-induced pure red cell aplasia refractory to immunosuppressive drugs. Nephrol Dial Transpl. 2008;23:2416–8.CrossRef
14.
Zurück zum Zitat Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108:1830–4.CrossRefPubMed Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108:1830–4.CrossRefPubMed
15.
Zurück zum Zitat Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848–55.CrossRefPubMed Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848–55.CrossRefPubMed
Metadaten
Titel
Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone
verfasst von
Daisuke Katagiri
Maki Shibata
Takashi Katsuki
Shoichi Masumoto
Ai Katsuma
Eri Minami
Taro Hoshino
Tsuyoshi Inoue
Manami Tada
Fumihiko Hinoshita
Publikationsdatum
01.10.2010
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 5/2010
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0318-8

Weitere Artikel der Ausgabe 5/2010

Clinical and Experimental Nephrology 5/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.